Corcept Therapeutics vs Supernus Pharmaceuticals
Corcept Therapeutics reported revenue of $761 million in fiscal 2025, about the same as Supernus Pharmaceuticals' $719 million in fiscal 2025. Corcept Therapeutics' revenue grew 12.8% in its latest year, and Supernus Pharmaceuticals' grew 8.6%. Corcept Therapeutics had an operating margin of 5.9%, against -8.7% at Supernus Pharmaceuticals. Free cash flow was $142 million at Corcept Therapeutics and $46 million at Supernus Pharmaceuticals.
Side by side
| Corcept Therapeutics | Supernus Pharmaceuticals | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $761M | $719M |
| Revenue growth | 12.8% | 8.6% |
| Revenue growth a year, last 5 years | 16.6% | 6.7% |
| Gross margin | 98.3% | 89.6% |
| Operating margin | 5.9% | −8.7% |
| Net margin | 13.1% | −5.4% |
| Free cash flow | $142M | $46M |
| Free cash flow margin | 18.6% | 6.4% |
| Return on capital | 15.7% | −7.4% |
| Net debt to EBITDA | −8.1x | −10.5x |
| Dividends and buybacks | $173M | $0M |
| Change in diluted share count | 5.7% | 0.9% |
| Last close | $72.77 | $26.16 |
| P/E at the last close | 57.3× | — |
| Insider trades, last 12 months | bought $3.3 million, sold $92.5 million | sold $10.3 million |
| Piotroski F-score | 3 of 9 | 4 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Corcept TherapeuticsSupernus Pharmaceuticals
Operating margin
Percent of revenue
Corcept TherapeuticsSupernus Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Corcept TherapeuticsSupernus Pharmaceuticals
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Corcept Therapeutics and Supernus Pharmaceuticals pages.